These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9777929)

  • 1. Speech disturbance and marked decrease in function seen in several older patients on olanzapine.
    Gaile S; Noviasky JA
    J Am Geriatr Soc; 1998 Oct; 46(10):1330-1. PubMed ID: 9777929
    [No Abstract]   [Full Text] [Related]  

  • 2. Olanzapine toxicity in unconjugated hyperbilirubinaemia (Gilbert's syndrome).
    Martín-Escudero JC; Dueñas-Laíta A; Pérez-Castrillón JL; Herreros-Fernández V
    Br J Psychiatry; 2003 Mar; 182():267. PubMed ID: 12611795
    [No Abstract]   [Full Text] [Related]  

  • 3. Olanzapine: extrapyramidal side effects in the elderly.
    Granger AS; Hanger HC
    Aust N Z J Med; 1999 Jun; 29(3):371-2. PubMed ID: 10868502
    [No Abstract]   [Full Text] [Related]  

  • 4. Olanzapine/risperidone and diabetes risk.
    Lee DW; Fowler RB
    J Clin Psychiatry; 2003 Jul; 64(7):847-8; author reply 848. PubMed ID: 12934988
    [No Abstract]   [Full Text] [Related]  

  • 5. Olanzapine can worsen parkinsonism.
    Jiménez-Jiménez FJ; Tallón-Barranco A; Ortí-Pareja M; Zurdo M; Porta J; Molina JA
    Neurology; 1998 Apr; 50(4):1183-4. PubMed ID: 9566425
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute hepatocellular-cholestatic liver injury after olanzapine therapy.
    Jadallah KA; Limauro DL; Colatrella AM
    Ann Intern Med; 2003 Feb; 138(4):357-8. PubMed ID: 12585842
    [No Abstract]   [Full Text] [Related]  

  • 7. Olanzapine and tardive dyskinesia.
    Woods SW
    Br J Psychiatry; 1999 Oct; 175():391-2. PubMed ID: 10789313
    [No Abstract]   [Full Text] [Related]  

  • 8. Olanzapine-associated priapism.
    Gordon M; de Groot CM
    J Clin Psychopharmacol; 1999 Apr; 19(2):192. PubMed ID: 10211928
    [No Abstract]   [Full Text] [Related]  

  • 9. Tardive dyskinesia associated with olanzapine.
    Herrán A; Vázquez-Barquero JL
    Ann Intern Med; 1999 Jul; 131(1):72. PubMed ID: 10391826
    [No Abstract]   [Full Text] [Related]  

  • 10. Possible neuroleptic malignant syndrome associated with olanzapine.
    Nyfort-Hansen K; Alderman CP
    Ann Pharmacother; 2000 May; 34(5):667. PubMed ID: 10852098
    [No Abstract]   [Full Text] [Related]  

  • 11. Olanzapine and pancreatitis.
    Hagger R; Brown C; Hurley P
    Br J Psychiatry; 2000 Dec; 177():567. PubMed ID: 11102343
    [No Abstract]   [Full Text] [Related]  

  • 12. Olanzapine-induced agranulocytosis: a case report and review of the literature.
    Tolosa-Vilella C; Ruiz-Ripoll A; Mari-Alfonso B; Naval-Sendra E
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):411-4. PubMed ID: 11817522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine and rhabdomyolysis.
    Shuster J
    Nursing; 2000 Sep; 30(9):87. PubMed ID: 11022553
    [No Abstract]   [Full Text] [Related]  

  • 14. [Neuroleptic malignant syndrome and atypical antipsychotics].
    Canora Lebrato J; Bermúdez García JM; Alvarez García ML; Rico Irles J
    Med Clin (Barc); 2000 Sep; 115(7):279. PubMed ID: 11013157
    [No Abstract]   [Full Text] [Related]  

  • 15. Olanzapine: weight gain and therapeutic efficacy.
    Gupta S; Droney T; Al-Samarrai S; Keller P; Frank B
    J Clin Psychopharmacol; 1999 Jun; 19(3):273-5. PubMed ID: 10350036
    [No Abstract]   [Full Text] [Related]  

  • 16. Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine.
    Hägg S; Mjörndal T; Lindqvist L
    J Clin Psychopharmacol; 2001 Feb; 21(1):113-5. PubMed ID: 11199936
    [No Abstract]   [Full Text] [Related]  

  • 17. Olanzepine-induced tardive dyskinesia.
    Bella VL; Piccoli F
    Br J Psychiatry; 2003 Jan; 182():81-2. PubMed ID: 12509329
    [No Abstract]   [Full Text] [Related]  

  • 18. Pustular eruption induced by olanzapine, a novel antipsychotic agent.
    Adams BB; Mutasim DF
    J Am Acad Dermatol; 1999 Nov; 41(5 Pt 2):851-3. PubMed ID: 10534668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy should drive atypical antipsychotic treatment.
    Citrome LL
    BMJ; 2003 Feb; 326(7383):283. PubMed ID: 12561827
    [No Abstract]   [Full Text] [Related]  

  • 20. Atypical antipsychotic drugs and hyperglycemia in adolescents.
    Koller E; Malozowski S; Doraiswamy PM
    JAMA; 2001 Nov; 286(20):2547-8. PubMed ID: 11722267
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.